Sonalee Agarwal

755 total citations
23 papers, 599 citations indexed

About

Sonalee Agarwal is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Sonalee Agarwal has authored 23 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Sonalee Agarwal's work include Multiple Sclerosis Research Studies (13 papers), Polyomavirus and related diseases (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Sonalee Agarwal is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Polyomavirus and related diseases (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Sonalee Agarwal collaborates with scholars based in United States, United Kingdom and Switzerland. Sonalee Agarwal's co-authors include Judith J. Stephenson, Siddhesh Kamat, Qian Cai, Hiangkiat Tan, Sujata P. Sarda, Michael Hutchinson, Eva Havrdová, Robert J. Fox, John Foley and Krithika Rajagopalan and has published in prestigious journals such as Neurology, The American Journal of Gastroenterology and Journal of Neurology.

In The Last Decade

Sonalee Agarwal

20 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sonalee Agarwal United States 13 450 150 121 113 100 23 599
Jacqueline Nicholas United States 12 370 0.8× 108 0.7× 56 0.5× 88 0.8× 110 1.1× 47 507
Hadj Benzerdjeb France 6 713 1.6× 233 1.6× 70 0.6× 84 0.7× 255 2.5× 6 852
Aurora Zanghì Italy 16 462 1.0× 174 1.2× 47 0.4× 87 0.8× 169 1.7× 50 648
Nuwan Kurukulasuriya United States 13 369 0.8× 161 1.1× 67 0.6× 81 0.7× 91 0.9× 38 552
Johannes Lorscheider Switzerland 12 434 1.0× 127 0.8× 39 0.3× 95 0.8× 145 1.4× 28 557
Teresa Bagulho United States 5 385 0.9× 172 1.1× 37 0.3× 42 0.4× 146 1.5× 7 489
Sibyl Wray United States 14 442 1.0× 157 1.0× 48 0.4× 59 0.5× 175 1.8× 58 628
C. H. Polman Netherlands 10 788 1.8× 252 1.7× 77 0.6× 67 0.6× 372 3.7× 13 912
Alexandra Degenhardt United Kingdom 9 655 1.5× 137 0.9× 45 0.4× 98 0.9× 243 2.4× 10 769
Mark Slee Australia 12 257 0.6× 111 0.7× 39 0.3× 91 0.8× 214 2.1× 41 518

Countries citing papers authored by Sonalee Agarwal

Since Specialization
Citations

This map shows the geographic impact of Sonalee Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonalee Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonalee Agarwal more than expected).

Fields of papers citing papers by Sonalee Agarwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonalee Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonalee Agarwal. The network helps show where Sonalee Agarwal may publish in the future.

Co-authorship network of co-authors of Sonalee Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Sonalee Agarwal. A scholar is included among the top collaborators of Sonalee Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonalee Agarwal. Sonalee Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Agarwal, Sonalee, et al.. (2020). Patient Perspective on Hereditary Transthyretin-Mediated (hATTR) Amyloidosis: A Qualitative Review. Heart & Lung. 49(2). 213–213. 1 indexed citations
2.
Ajroud‐Driss, Senda, David Adams, Teresa Coelho, et al.. (2019). Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial (S27.007). Neurology. 92(15_supplement). 1 indexed citations
3.
Truty, Rebecca, et al.. (2019). Alnylam Act®: Heterogenous Disease Manifestations of Hereditary Transthyretin-Mediated Amyloidosis. Journal of Cardiac Failure. 25(8). S111–S112. 1 indexed citations
4.
Simon, Amy, Farrah Pompilus, William Querbes, et al.. (2018). Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations. Patient. 11(5). 527–537. 51 indexed citations
5.
Rudnick, Sean, Hélio Pedro, John J. Ko, et al.. (2018). The Patient Odyssey to Confirmed Acute Hepatic Porphyria Diagnosis: Clinical Characteristics and Healthcare Utilization of Patients Preceding Diagnosis of Acute Hepatic Porphyria. The American Journal of Gastroenterology. 113(Supplement). S500–S501. 1 indexed citations
6.
Agarwal, Sonalee, A. T. McManus, William Querbes, et al.. (2018). Developing an Algorithm to Identify Patients with Acute Intermittent Porphyria in an Administrative Claims Database. Value in Health. 21. S213–S213. 1 indexed citations
7.
Foley, John, Kavita Nair, Timothy R. Vollmer, et al.. (2017). Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Preference and Adherence. Volume 11. 1035–1048. 19 indexed citations
8.
Ziemssen, Tjalf, Glenn Phillips, Ruchit Shah, et al.. (2016). Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ). Journal of Neurology. 263(10). 1969–1983. 17 indexed citations
9.
Macdonell, Richard, Guy Nagels, David Laplaud, et al.. (2015). Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Multiple Sclerosis Journal. 22(7). 944–954. 23 indexed citations
10.
11.
Hutchinson, Michael, Robert J. Fox, Eva Havrdová, et al.. (2013). Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion. 30(4). 613–627. 60 indexed citations
12.
Nagels, Guy, Richard Macdonell, Per Soelberg Sørensen, et al.. (2013). Long-Term Prolonged-Release Fampridine Treatment and Health-Related Quality of Life Outcomes: Interim Results of the Enable Study. Value in Health. 16(7). A627–A627. 1 indexed citations
13.
Kappos, Ludwig, Ralf Gold, Douglas L. Arnold, et al.. (2013). Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study. Multiple Sclerosis Journal. 20(2). 243–252. 49 indexed citations
14.
Kita, Mariko, Robert J. Fox, J. Theodore Phillips, et al.. (2013). Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study. Multiple Sclerosis Journal. 20(2). 253–257. 38 indexed citations
15.
Stephenson, Judith J., David M. Kern, Sonalee Agarwal, et al.. (2012). Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Health and Quality of Life Outcomes. 10(1). 155–155. 37 indexed citations
16.
Agarwal, Sonalee, Ludwig Kappos, Ralf Gold, et al.. (2012). Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102). Neurology. 78(Meeting Abstracts 1). P07.102–P07.102. 1 indexed citations
17.
O’Day, Ken, et al.. (2011). Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. Journal of Medical Economics. 14(5). 617–627. 36 indexed citations
18.
Halpern, Rachel, et al.. (2011). Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis. Advances in Therapy. 28(9). 761–775. 28 indexed citations
19.
Tan, Hiangkiat, Qian Cai, Sonalee Agarwal, Judith J. Stephenson, & Siddhesh Kamat. (2010). Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Advances in Therapy. 28(1). 51–61. 199 indexed citations
20.
Kamat, Siddhesh, Krithika Rajagopalan, Judith J. Stephenson, & Sonalee Agarwal. (2009). Impact of Natalizumab on Patient-Reported Outcomes in a Clinical Practice Setting. Patient. 2(2). 105–112. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqueline Nicholas Breakdown of academic impact, for papers by Hadj Benzerdjeb Breakdown of academic impact, for papers by Aurora Zanghì Breakdown of academic impact, for papers by Nuwan Kurukulasuriya Breakdown of academic impact, for papers by Johannes Lorscheider Breakdown of academic impact, for papers by Teresa Bagulho Breakdown of academic impact, for papers by Sibyl Wray Breakdown of academic impact, for papers by C. H. Polman Breakdown of academic impact, for papers by Alexandra Degenhardt Breakdown of academic impact, for papers by Mark Slee
Rankless by CCL
2026